N-tert-butyl-1-methyl-1H-benzo[d]imidazol-2-amine | 41039-11-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: N-tert-butyl-1-methyl-1H-benzo[d]imidazol-2-amine
• 英文别名: 2-(tert-butylamino)-1-methylbenzimidazole；tert-butyl-(1-methyl-1H-benzoimidazol-2-yl)-amine；2-tert.-Butylamino-1-methylbenzimidazol；N-tert-butyl-1-methylbenzimidazol-2-amine
• CAS: 41039-11-6
• 化学式: C₁₂H₁₇N₃
• 分子量: 203.287
• InChiKey: RBAUPCDTSZPCQS-UHFFFAOYSA-N

物化性质

• 熔点：
  148-151 °C
• 沸点：
  322.2±25.0 °C(Predicted)
• 密度：
  1.06±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  29.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  异氰酸叔丁酯 、 N-甲基-1,2-苯二胺 在 cobalt(II) acetate 、 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 24.0h， 以44%的产率得到N-tert-butyl-1-methyl-1H-benzo[d]imidazol-2-amine
  参考文献：
  名称：

  含异腈的钴催化的2-氨基苯胺的有氧氧化环化：可轻松获得2-氨基苯并咪唑

  摘要：

  开发了由2-氨基苯胺合成的无配体和无添加剂的好氧钴催化合成2-氨基苯并咪唑。各种氨基苯胺和异腈经过有效偶联，以中等至极好的收率提供了取代的2-氨基苯并咪唑。该协议可有效访问未取代的2-氨基苯并咪唑。

  DOI：

  10.1002/cctc.201902011

文献信息

• Sustainable Synthesis of Diverse Privileged Heterocycles by Palladium-Catalyzed Aerobic Oxidative Isocyanide Insertion
  作者：Tjøstil Vlaar、Razvan C. Cioc、Pieter Mampuys、Bert U. W. Maes、Romano V. A. Orru、Eelco Ruijter

  DOI：10.1002/anie.201207410

  日期：2012.12.21

  O2 in, H2O out: Various diamines and related bisnucleophiles readily undergo oxidative isocyanide insertion with Pd(OAc)2 (1 mol %) as the catalyst and O2 as the terminal oxidant to give a diverse array of medicinally relevant N heterocycles. The utility of this highly sustainable method is demonstrated by a formal synthesis of the antihistamines astemizole and norastemizole.

  O 2 in，H 2 O out：各种二胺和相关的双亲核试剂易于经历氧化异氰化物的插入，其中Pd（OAc）2（1 mol％）作为催化剂，O 2作为末端氧化剂，可得到多种与医学相关的N杂环。抗组胺药阿司咪唑和去甲阿司咪唑的正式合成证明了这种高度可持续性方法的实用性。
• Cobalt-Catalyzed Oxidative Isocyanide Insertion to Amine-Based Bisnucleophiles: Diverse Synthesis of Substituted 2-Aminobenzimidazoles, 2-Aminobenzothiazoles, and 2-Aminobenzoxazoles
  作者：Tong-Hao Zhu、Shun-Yi Wang、Gao-Nan Wang、Shun-Jun Ji

  DOI：10.1002/chem.201300239

  日期：2013.5.3

  Cobalt catalysis: Synthesis of substituted 2‐aminobenzimidazoles, 2‐aminobenzothiazoles, and 2‐aminobenzoxazoles was achieved by using cobalt(II) acetate catalyzed isocyanide insertion to o‐diaminobenzene, 2‐aminobenzenethiol, and 2‐aminophenol derivatives in 1,4‐dioxane (see scheme). It was found that the reaction proceeded efficiently to give the desired products in up to 95 % isolated yields by

  钴催化：使用乙酸钴（II）催化异氰酸酯插入1,4-二恶烷中的邻-二氨基苯，2-氨基苯硫醇和2-氨基苯酚衍生物，可合成取代的2-氨基苯并咪唑，2-氨基苯并噻唑和2-氨基苯并恶唑（请参阅方案）。发现该反应有效地进行，通过一步形成CN和CS（O，N），以高达95％的分离产率得到所需的产物。
• Pyrazolo pyrimidines useful as aurora kinase inhibitors
  申请人：Oslob D. Johan

  公开号：US20070027166A1

  公开（公告）日：2007-02-01

  The present invention provides compounds having the formula: wherein A-B together represent one of the following structures: wherein one of is a double bond, as valency permits; and R 2 , R 4 , X 1A , X 2A , X 1B , X 2B , L 1 , L 2 , Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of Aurora mediated diseases.

  本发明提供具有以下结构的化合物：其中A-B一起代表以下结构之一：其中之一是双键，根据价性而定；而R2、R4、X1A、X2A、X1B、X2B、L1、L2、Y和Z如此处所定义，以及其制药组合物，如此处总体描述和所述的亚类，这些化合物可用作蛋白激酶（例如Aurora）的抑制剂，因此可用于例如治疗由Aurora介导的疾病。
• Spiropyrrolidine derived antiviral agents
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US11339170B1

  公开（公告）日：2022-05-24

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

  本发明揭示了式（I）的化合物及其药学上可接受的盐：可抑制冠状病毒复制活性。本发明还涉及包含式（I）的化合物或其药学上可接受的盐的制药组合物，以及治疗或预防受冠状病毒感染的患者的方法，包括向患者施用式（I）的化合物或其药学上可接受的盐的治疗有效量。
• 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators
  申请人：Wang Jiabing

  公开号：US20080125399A1

  公开（公告）日：2008-05-29

  Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

  结构式（I）的化合物以组织选择性的方式调节雄激素受体（AR）。这些化合物有助于增强肌肉张力减弱和治疗由雄激素缺乏引起或可以通过雄激素治疗改善的疾病，包括骨质疏松症、骨质疏松、糖皮质激素诱导的骨质疏松症、牙周病、骨折、骨重建手术后的骨损伤、肌肉萎缩、衰弱、老化皮肤、男性性腺功能减退、女性绝经后症状、动脉硬化、高胆固醇血症、高脂血症、肥胖症、再生障碍性贫血和其他造血系统疾病、炎性关节炎和关节修复、艾滋病消耗综合征、前列腺癌、良性前列腺增生症（BPH）、癌症消耗综合征、阿尔茨海默病、肌营养不良、认知能力下降、性功能障碍、睡眠呼吸暂停、抑郁症、早发性卵巢衰竭和自身免疫性疾病，可单独使用或与其他活性剂联合使用。